FIT BIOTECH OY
Company announcement
March 18, 2016 at 10.00 am
FIT Biotech Oy’s Annual Report 2015 published
The Finnish version of FIT Biotech Oy’s Annual Report for the year 2015 has been published today. The English version of the Annual Report will be published on Tuesday, March 22, 2016. Annual Report contains the financial statements and the report of the Board of Directors.
FIT BIOTECH OY
Board of Directors
Further information:
Rabbe Slätis
CEO, FIT Biotech Oy
Email: rabbe.slatis@fitbiotech.com
Tel.: +358 40 840 6749
Certified Advisor: Translink Corporate Finance Oy, tel. +358 20 743 2790
FIT Biotech in brief
FIT Biotech Oy is a biotechnology company established in 1995 that develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland market maintained by Nasdaq Helsinki Oy.
DISTRIBUTION:
NASDAQ OMX Helsinki
Principal media
www.fitbiotech.com
HUG#1995813
